Skip to main content
Premium Trial:

Request an Annual Quote

ForteBio Hires Octet Distributors in Australia, New Zealand, and Switzerland

NEW YORK (GenomeWeb News) — ForteBio, a developer of label-free, real-time systems for biomolecular interaction analysis, this week said it has hired two distributors to sell its Octet instruments and related consumables in parts of Europe and the South Pacific.
 
Swiss company Bucher Biotec will exclusively distribute ForteBio’s products in that country, while Millennium Science, an Australian distributor, will sell the products in that nation and in neighboring New Zealand.
 
ForteBio CEO Winnie Wan said in a statement that the distribution deals “will accelerate our efforts to further penetrate and serve these key markets,” which have shown a “growing demand for label-free solutions that are flexible, cost-efficient and accurate.”
    
The company’s Octet tools are “designed to help accelerate the selection and characterization of therapeutic candidates by generating real-time kinetic and quantitative results quickly and easily,” ForteBio said in the statement.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.